MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Cryptococcal Antigen Screening Plus Sertraline

Phase 3
Terminated
Conditions
Cryptococcosis
Cryptococcal Infections
AIDS-Related Opportunistic Infections
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2016-12-23
Last Posted Date
2020-06-09
Lead Sponsor
University of Minnesota
Target Recruit Count
22
Registration Number
NCT03002012
Locations
🇺🇬

Infectious Disease Institute, Makerere University, Kampala, Uganda

Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.

Phase 2
Terminated
Conditions
Crohn's Disease Aggravated
Interventions
Other: Placebo
First Posted Date
2016-12-19
Last Posted Date
2016-12-19
Lead Sponsor
University Hospital, Lille
Target Recruit Count
35
Registration Number
NCT02997059
Locations
🇫🇷

CHRU, Hôpital Claude Huriez, Lille, France

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Phase 2
Completed
Conditions
Vulvovaginitis
Yeast Infection
Yeast Infection Vaginal
Candidiasis, Vulvovaginal
Interventions
Drug: Oral Encochleated Amphotericin B (CAMB)
First Posted Date
2016-11-22
Last Posted Date
2018-11-02
Lead Sponsor
Matinas BioPharma Nanotechnologies, Inc.
Target Recruit Count
137
Registration Number
NCT02971007
Locations
🇺🇸

Lawrence OB/GYN, Lawrenceville, New Jersey, United States

🇺🇸

Advanced Research Institute Inc, New Port Richey, Florida, United States

🇺🇸

PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States

and more 20 locations

the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations

Phase 2
Completed
Conditions
Intra-abdominal Perforation
Interventions
First Posted Date
2016-10-21
Last Posted Date
2016-10-21
Lead Sponsor
Nanjing PLA General Hospital
Target Recruit Count
223
Registration Number
NCT02941068

Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2016-06-22
Last Posted Date
2017-03-09
Lead Sponsor
Eisai Inc.
Target Recruit Count
48
Registration Number
NCT02809768

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

First Posted Date
2016-05-06
Last Posted Date
2024-02-06
Lead Sponsor
University of Pennsylvania
Target Recruit Count
8
Registration Number
NCT02765256
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Phase 2
Completed
Conditions
Fungal Infection
Fungemia
Invasive Candidiasis
Candidemia
Mycoses
Interventions
Drug: intravenous placebo
Drug: oral placebo
First Posted Date
2016-04-12
Last Posted Date
2020-12-08
Lead Sponsor
Cidara Therapeutics Inc.
Target Recruit Count
207
Registration Number
NCT02734862
Locations
🇪🇸

University Hospital La Paz, Madrid, Spain

🇧🇪

UCL Saint-LUC, Brussels, Belgium

🇺🇸

Virginia Tech, Carillion School of Medicine, Roanoke, Virginia, United States

and more 60 locations

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Phase 2
Completed
Conditions
Candidiasis, Vulvovaginal
Mycoses
Yeast Infection
Moniliasis, Vulvovaginal
Vaginitis, Monilial
Interventions
Drug: CD101 Vaginal Gel (3%)
Drug: CD101 Vaginal Ointment (6%)
Drug: CD101 External gel (1%)
Drug: CD101 External ointment (1%)
First Posted Date
2016-04-11
Last Posted Date
2020-08-31
Lead Sponsor
Cidara Therapeutics Inc.
Target Recruit Count
126
Registration Number
NCT02733432
Locations
🇺🇸

Women's Medical Research, Clearwater, Florida, United States

🇺🇸

Augusta University, Augusta, Georgia, United States

🇺🇸

Seattle Women's Health, Research, Gynecology, Seattle, Washington, United States

and more 21 locations

Study of Potential for Interaction of Fluconazole With F901318

Phase 1
Completed
Conditions
Invasive Aspergillosis
Interventions
First Posted Date
2016-04-06
Last Posted Date
2017-02-02
Lead Sponsor
F2G Biotech GmbH
Target Recruit Count
20
Registration Number
NCT02730442
Locations
🇬🇧

CELERION, Belfast, Northern Ireland, United Kingdom

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Phase 2
Completed
Conditions
Vulvovaginal Candidiasis
Interventions
First Posted Date
2016-02-10
Last Posted Date
2019-07-12
Lead Sponsor
Scynexis, Inc.
Target Recruit Count
96
Registration Number
NCT02679456
Locations
🇩🇴

Hospital Dr. Francisco E. Moscoso Puello, Santo Domingo, Dominican Republic

🇩🇴

Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic

© Copyright 2025. All Rights Reserved by MedPath